4-{[4-(pyrimidin-2-yl)piperazin-1-yl]methyl}-1,3-thiazol-2-amine

Catalog No. :
ACTVGE841
CAS No. :
1096943-32-6
Molecular Formula :
C12H16N6S
Molecular Weight :
276.37

IUPAC Name:4-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)thiazol-2-amine

4-{[4-(pyrimidin-2-yl)piperazin-1-yl]methyl}-1,3-thiazol-2-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$244.00Login to see priceInquiryInquiry
250mg98%$502.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-{[4-(pyrimidin-2-yl)piperazin-1-yl]methyl}-1,3-thiazol-2-amine
IUPAC Name4-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)thiazol-2-amine
MDL No.MFCD12460117
Molecular FormulaC12H16N6S
Molecular Weight276.37
SMILESNC1=NC(CN2CCN(C3=NC=CC=N3)CC2)=CS1
InChI KeyGHRLROGRYATDON-UHFFFAOYSA-N
Synonym4-{[4-(Pyrimidin-2-yl)piperazin-1-yl]methyl}-1,3-thiazol-2-amine;2-Thiazolamine, 4-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]-
CAS No.1096943-32-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACTVGE841 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWBRG526 route compound structure diagram
    ACWBRG52698020-38-3 In Stock
  2. Plus
  3. ACRKMW197 route compound structure diagram
    ACRKMW19778069-54-2 In Stock
  4. Then
  5. ACTVGE841 route product structure diagram
    ACTVGE8411096943-32-6
Inquiry

2. ACTVGE841 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRKMW197 route compound structure diagram
    ACRKMW19778069-54-2 In Stock
  4. Then
  5. ACTVGE841 route product structure diagram
    ACTVGE8411096943-32-6
Inquiry

Comments (0)